Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s00280-014-2609-3
Published Online: 2014-10-17
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hochster, H. S.
Uboha, N.
Messersmith, W.
Gold, P. J.
ONeil, B. H.
Cohen, D.
Denlinger, C.
Cohen, S.
Leichman, C. G.
Leichman, L.
Text and Data Mining valid from 2014-10-17